Chemotherapy-induced neuropathy: incidence, natural history, measurement, prevention, and treatment

Published on August 31, 2016   43 min

Other Talks in the Series: Topical Talks

0:00
Good day. This is Charles Loprinzi from Mayo Clinic in Rochester, Minnesota. I'm happy to talk about Chemotherapy-Induced Neuropathy.
0:09
Talking about the incidence, natural history, measurement, prevention and treatment aspects. I'll start off by talking about the incidence and causative agents.
0:20
Chemotherapy-induced neuropathy is a very common problem for patients who are receiving chemotherapy. It's probably the most bothersome chronic toxicity that we, as oncologists, see with chemotherapy. Paclitaxel and oxaliplatin are two of the biggest offenders, they cause a fair amount of neuropathy each time, and they're used quite frequently. So I estimate that this is probably 80% of the neuropathy that we see in clinical oncology. Probably equal between the two different drugs. There are other drugs that can cause chemotherapy-induced neuropathy. Other platinum agents such a cisplatin or carboplatin. Other taxanes such as docetaxel. And then there are a variety of other drugs and I've listed some there, that you could see. These drugs are used less often than the above noted drugs.
Hide

Chemotherapy-induced neuropathy: incidence, natural history, measurement, prevention, and treatment

Embed in course/own notes